Low-Dose Triple-Pill of Telmisartan, Amlodipine, and Indapamide for Initial Hypertension Treatment: A GRADE-Assessed Meta-analysis of Randomized Trials
High Blood Pressure & Cardiovascular Prevention · 2025
DOI: 10.1007/s40292-025-00751-8 ↗Kurz gefasst
Metaanalyse in der Zeitschrift High Blood Pressure & Cardiovascular Prevention, 2025. Verfasst von Abdalhakim Shubietah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA. Hauptthemen laut MEDLINE: Amlodipine, Telmisartan, Hypertension, Blood Pressure. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: FDA-approved GMRx2, a single-pill combination of telmisartan, amlodipine, and indapamide, has shown potential for improving blood pressure (BP) control. AIM: We assessed the efficacy and safety of low-dose GMRx2 compared to placebo, or standard-care (monotherapy or dual therapy) in mild to moderate hypertension. METHODS: A meta-analysis of randomized controlled trials (RCTs) was conducted from PubMed, Embase, Cochrane, Scopus, and Web of Science from 2006 to June 2025. Random-effects model to pool mean difference (MD) for continuous outcomes and risk ratios (RR) for binary outcomes with 95% confidence intervals (CI). PROSPERO-ID: CRD420251108645 RESULTS: Four RCTs involving 1999 patients were included. Compared with control, low-dose GMRx2 significantly reduced office systolic BP at 4-6 weeks (MD -8.84 mmHg, 95% CI [-11.27; -6.46]) and 12 weeks (MD -5.52 mmHg, 95% CI [-6.85; -4.18]). It also increased the proportion of patients achieving target office BP at 4-6 weeks (66.7% vs. 50.2%, RR 1.20, 95% CI [1.08-1.43]) and 8-12 weeks (75.6% vs. 59.5%, RR 1.15, 95% CI [1.05-1.26]). No significant differences were observed in serious adverse events (P= 0.77) or treatment discontinuation (P= 0.30). However, low-dose GMRx2 had a higher incidence of hypokalemia (9% vs. 7%, RR 1.40, 95% CI [1.04-1.90]) and hyponatremia (5% vs. 3.7%, RR 1.59, 95% CI [1.04-2.42]). CONCLUSION: Low-dose GMRx2 provides superior BP reduction and a well-tolerated safety profile in patients with mild to moderate hypertension. Nonetheless, it may increase the risk of hypokalemia and hyponatremia. Larger and longer-term RCTs are warranted to confirm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.
- Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt. dr.elgendy.mo@gmail.com.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine.
- Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt.
- Division of Cardiovascular Medicine, University of Iowa, Iowa, IA, USA.
Zitieren
APA
Shubietah, A., Elgendy, M. S., Emara, A., Abdul-Hafez, H. A., Awashra, A., Elbably, I., Abuelazm, M., & Mhanna, M. (2025). Low-Dose Triple-Pill of Telmisartan, Amlodipine, and Indapamide for Initial Hypertension Treatment: A GRADE-Assessed Meta-analysis of Randomized Trials. High Blood Pressure & Cardiovascular Prevention. https://doi.org/10.1007/s40292-025-00751-8
Vancouver
Shubietah A, Elgendy MS, Emara A, Abdul-Hafez HA, Awashra A, Elbably I, et al. Low-Dose Triple-Pill of Telmisartan, Amlodipine, and Indapamide for Initial Hypertension Treatment: A GRADE-Assessed Meta-analysis of Randomized Trials. High Blood Pressure & Cardiovascular Prevention. 2025. doi:10.1007/s40292-025-00751-8
BibTeX
@article{Shubietah2025,
author = {Shubietah, Abdalhakim and Elgendy, Mohamed S and Emara, Ahmed and Abdul-Hafez, Hamza A and Awashra, Ameer and Elbably, Ibrahim and Abuelazm, Mohamed and Mhanna, Mohammed},
title = {Low-Dose Triple-Pill of Telmisartan, Amlodipine, and Indapamide for Initial Hypertension Treatment: A GRADE-Assessed Meta-analysis of Randomized Trials},
journal = {High Blood Pressure & Cardiovascular Prevention},
year = {2025},
doi = {10.1007/s40292-025-00751-8}
}
EUVIMED